Korea Exchange · Healthcare
Bukwang Pharmaceutical stock from India: price, numbers and tax
Bukwang Pharmaceutical (003000) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Bukwang Pharmaceutical at a glance
- Price
- ₩4,055.00-₩215.00 (5.04%)
- Market cap
- ₩400.09B
- Day range
- ₩3,900.00 – ₩4,225.00
- P/E
- 67.18
- Dividend yield
- 3.08%
- Volume
- 455.25K
- 1 month
- -0.86%
- 6 months
- -46.22%
- YTD
- +7.13%
- 1 year
- +14.55%
- 5 years
- -69.74%
Bukwang Pharmaceutical statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩200.7B | ₩160.1B | ₩125.9B | ₩190.9B | ₩182.5B |
| Gross profit | ₩95.7B | ₩74.3B | ₩50.0B | ₩79.4B | ₩75.8B |
| Operating income | ₩14.2B | ₩1.6B | −₩37.5B | −₩230.6M | ₩5.6B |
| Net income | ₩12.6B | −₩2.6B | −₩31.3B | −₩2.5B | −₩916.6M |
| Earnings per share | ₩152.00 | −₩38.59 | −₩458.00 | −₩36.15 | −₩13.39 |
| EBITDA | ₩19.7B | ₩7.6B | −₩31.5B | ₩4.9B | ₩11.4B |
| Total assets | ₩502.2B | ₩373.2B | ₩429.0B | ₩400.9B | ₩397.4B |
| Total debt | ₩80.3B | ₩79.4B | ₩79.4B | ₩930.8M | ₩1.6B |
| Cash and short-term investments | ₩216.2B | ₩130.1B | ₩151.2B | ₩85.5B | ₩84.3B |
| Shareholders' equity | ₩341.5B | ₩243.7B | ₩226.3B | ₩263.2B | ₩269.6B |
| Operating cash flow | ₩18.5B | ₩34.4B | −₩10.5B | ₩16.5B | ₩26.5B |
| Free cash flow | ₩11.2B | ₩31.7B | −₩13.3B | ₩11.5B | ₩25.7B |
| Capital expenditure | −₩7.3B | −₩2.6B | −₩2.8B | −₩5.0B | −₩789.5M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| HLB Pharmaceutical | 047920.KQ | ₩13,130.00 | ₩430.65B |
| Dong-A ST | 170900.KS | ₩34,950.00 | ₩337.05B |
| Suheung | 008490.KS | ₩20,250.00 | ₩225.51B |
| Huons | 243070.KQ | ₩19,000.00 | ₩221.38B |
| Boditech Med | 206640.KQ | ₩9,790.00 | ₩212.52B |
| BNC Korea | 256840.KQ | ₩3,060.00 | ₩209.29B |
| Yungjin Pharm. | 003520.KS | ₩1,035.00 | ₩189.29B |
| Daewon Pharmaceutical | 003220.KS | ₩8,190.00 | ₩175.54B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Bukwang Pharmaceutical from India
What Bukwang Pharmaceutical does
Bukwang Pharmaceutical Co., Ltd., a South Korean-based enterprise, conducts pharmaceutical operations both domestically and across international markets. The company manufactures a diverse array of pharmaceutical formats, encompassing oral solids, injectables, liquid solutions, and topical preparations like external-use solutions and ointments. Bukwang Pharmaceutical operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Bukwang Pharmaceutical shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.